Similar articles

• Comparing cost aspects of coronary artery bypass graft surgery with coronary artery stenting.

  Birim Ö, Bogers AJ, Kappetein AP. Birim Ö, et al. J Cardiovasc Surg (Torino). 2012 Oct;53(5):641-50. Epub 2012 Jan 17. J Cardiovasc Surg (Torino). 2012. PMID: 22252542 Review.
• Cost-effectiveness of bypass surgery versus stenting in patients with multivessel coronary artery disease.

  Yock CA, Boothroyd DB, Owens DK, Garber AM, Hlatky MA. Yock CA, et al. Am J Med. 2003 Oct 1;115(5):382-9. doi: 10.1016/s0002-9343(03)00296-1. Am J Med. 2003. PMID: 14553874 Clinical Trial.
• Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).

  Eisenstein EL, Leon MB, Kandzari DE, Mauri L, Edwards R, Kong DF, Cowper PA, Anstrom KJ; ENDEAVOR III Investigators. Eisenstein EL, et al. JACC Cardiovasc Interv. 2009 Dec;2(12):1199-207. doi: 10.1016/j.jcin.2009.10.009. JACC Cardiovasc Interv. 2009. PMID: 20129546 Clinical Trial.
• Cost-effectiveness of the Endeavor stent in de novo native coronary artery lesions updated with contemporary data.

  Remak E, Manson S, Hutton J, Brasseur P, Olivier E, Gershlick A. Remak E, et al. EuroIntervention. 2010 Feb;5(7):826-32. doi: 10.4244/eijv5i7a138. EuroIntervention. 2010. PMID: 20142198
• Cost-effectiveness of alternative approaches to the management of chronic obstructive coronary artery disease.

  Amin AP, Cohen DJ. Amin AP, et al. Rev Cardiovasc Med. 2009;10 Suppl 2:S3-13. doi: 10.3909/ricm10S20002. Rev Cardiovasc Med. 2009. PMID: 19898279 Review.